Correction to “EMA commentary on the guideline on quality, nonclinical and clinical aspects of medicinal products containing genetically modified cells”
{"title":"Correction to “EMA commentary on the guideline on quality, nonclinical and clinical aspects of medicinal products containing genetically modified cells”","authors":"","doi":"10.1002/bcp.70033","DOIUrl":null,"url":null,"abstract":"<p>\n <span>Celis, P</span>, <span>Farinelli, G</span>, <span>Hidalgo-Simon, A</span>, et al. <span>EMA commentary on the guideline on quality, nonclinical and clinical aspects of medicinal products containing genetically modified cells</span>. <i>Br J Clin Pharmacol</i>. <span>2024</span>; <span>90</span>(<span>5</span>): <span>1203</span>–<span>1212</span>. 10.1111/bcp.16047</p><p>The information tab (and the pdf version, on the first page) erroneously mention Research Funding by Novo Nordisk Foundation. This is not correct: this gives the wrong impression that the article (or the guideline it refers to) was prepared with funding by Novo Nordisk, which was not the case.</p><p>This creates confusion and reputational damage for European Medicines Agency (EMA), as EMA cannot be associated with perceived funding from a single pharmaceutical company. It is also in conflict with the our <i>POLICY/0015</i> <i>on publication by EMA staff and EMA scientific committee members on EMA's work</i>.</p><p>No change is needed to the funding information include in the Acknowledgement section.</p><p>We apologize for this error.</p>","PeriodicalId":9251,"journal":{"name":"British journal of clinical pharmacology","volume":"91 4","pages":"1285"},"PeriodicalIF":3.1000,"publicationDate":"2025-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/bcp.70033","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British journal of clinical pharmacology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/bcp.70033","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Celis, P, Farinelli, G, Hidalgo-Simon, A, et al. EMA commentary on the guideline on quality, nonclinical and clinical aspects of medicinal products containing genetically modified cells. Br J Clin Pharmacol. 2024; 90(5): 1203–1212. 10.1111/bcp.16047
The information tab (and the pdf version, on the first page) erroneously mention Research Funding by Novo Nordisk Foundation. This is not correct: this gives the wrong impression that the article (or the guideline it refers to) was prepared with funding by Novo Nordisk, which was not the case.
This creates confusion and reputational damage for European Medicines Agency (EMA), as EMA cannot be associated with perceived funding from a single pharmaceutical company. It is also in conflict with the our POLICY/0015on publication by EMA staff and EMA scientific committee members on EMA's work.
No change is needed to the funding information include in the Acknowledgement section.
期刊介绍：
Published on behalf of the British Pharmacological Society, the British Journal of Clinical Pharmacology features papers and reports on all aspects of drug action in humans: review articles, mini review articles, original papers, commentaries, editorials and letters. The Journal enjoys a wide readership, bridging the gap between the medical profession, clinical research and the pharmaceutical industry. It also publishes research on new methods, new drugs and new approaches to treatment. The Journal is recognised as one of the leading publications in its field. It is online only, publishes open access research through its OnlineOpen programme and is published monthly.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
